Roivant Sciences (ROIV) Change in Acquisitions & Divestments (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Change in Acquisitions & Divestments came in at $568.2 million in Q2 2026, down 21.08% on a YoY basis from $720.0 million in Q2 2025, and down 79.3% quarter-over-quarter from $2.7 billion in Q4 2025.
Analysis
Roivant Sciences (ROIV) Change in Acquisitions & Divestments (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has reported Change in Acquisitions & Divestments for 5 consecutive years, with $568.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Change in Acquisitions & Divestments fell 21.08% year-over-year to $568.2 million; the trailing twelve-month figure through Jun 2026 stood at $5.1 billion (up 205.84% YoY), and the FY2026 full-year result was $2.2 billion, up 11.48% from the prior year.
- Change in Acquisitions & Divestments slipped to $568.2 million in Q2 2026 per ROIV's latest filing, from $2.7 billion in the prior quarter.
- Across five years, Change in Acquisitions & Divestments topped out at $2.7 billion in Q4 2025 and bottomed at $568.2 million in Q2 2026.
- Historically, Change in Acquisitions & Divestments has averaged $1.2 billion across 3 years, with a median of $960.0 million in 2024.
- The sharpest annual moves came in 2025 and 2026: Change in Acquisitions & Divestments soared 185.94% in 2025, then dropped 21.08% in 2026.
- Over 3 years, Change in Acquisitions & Divestments stood at $960.0 million in 2024, then jumped by 185.94% to $2.7 billion in 2025, then slumped by 79.3% to $568.2 million in 2026.
- According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $568.2 million, $2.7 billion, and $1.1 billion for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 210.69 Bn | 196.70 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.20 Bn | 178.03 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.15 Bn | 124.29 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.89 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.70 Bn | 56.51 Bn | 1.37 Bn |
| 6 | Moderna | 54.73 Bn | 49.59 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.11 Bn | 30.80 Bn | 992.69 Mn |
| 8 | Biogen | 31.27 Bn | 29.99 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.38 Bn | 30.38 Bn | 1.16 Mn |
| 10 | Insmed | 28.13 Bn | 26.97 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 568.19 Mn |
| Dec 31, 2025 | 2.75 Bn |
| Sep 30, 2025 | 1.11 Bn |
| Jun 30, 2025 | 720.00 Mn |
| Dec 31, 2024 | 960.00 Mn |
| Dec 31, 2021 | 320.17 Mn |
| Dec 31, 2020 | -320.17 Mn |